Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lannett Kicks Off Insulin Glargine Trial

Firm Eyes 2023 Filing And 2024 Launch For US Interchangeable Biosimilar Lantus Rival

Mar 29 2022

• By David Wallace

Road years 2022 2023 2024 — The road to an insulin glargine launch stretches to 2024 for Lannett • Source: thodsapol thongdeekhieo / Alamy Stock Photo

Related Content

Lannett Looks To Transform Company With Five Pipeline Assets

Aug 27 2021

Lannett On Track To Launch Insulin Glargine By 2023

Mar 11 2021

First Interchangeable Biosimilar Launched In US

Nov 16 2021

Will Eli Lilly’s Rezvoglar Be Able To Compete With Interchangeable Semglee?

Dec 23 2021

Lannett Advances Its Insulin Glargine Biosimilar

Dec 20 2021

New York Exchange Gives Lannett Six Months To Meet Standards

Mar 29 2022

Sandoz Partner Gan & Lee Wraps Phase III Insulin Glargine Trial

Oct 21 2021

Related Companies

Lannett Company, Inc.

Additional Topics

United States Biosimilars Clinical Trials BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.